Tabula Rasa HealthCare (TRHC) EPS Estimated At $-0.06; Glg Has Cut Its Merck & Co (MRK) Holding

August 1, 2017 - By Dolores Ford

Analysts expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) to report $-0.06 EPS on August, 7.After having $-0.11 EPS previously, Tabula Rasa HealthCare Inc’s analysts see -45.45% EPS growth. The stock increased 5.55% or $0.82 during the last trading session, reaching $15.6. About shares traded. Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has 0.00% since August 1, 2016 and is . It has underperformed by 16.70% the S&P500.

Glg Llc decreased Merck & Co Inc (MRK) stake by 14.25% reported in 2016Q4 SEC filing. Glg Llc sold 30,904 shares as Merck & Co Inc (MRK)’s stock declined 2.46%. The Glg Llc holds 185,977 shares with $10.95 million value, down from 216,881 last quarter. Merck & Co Inc now has $174.72 billion valuation. The stock decreased 0.36% or $0.23 during the last trading session, reaching $63.88. About shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since August 1, 2016 and is uptrending. It has outperformed by 0.16% the S&P500.

Among 3 analysts covering Tabula Rasa HealthCare (NASDAQ:TRHC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tabula Rasa HealthCare had 3 analyst reports since October 24, 2016 according to SRatingsIntel. As per Monday, October 24, the company rating was initiated by Wells Fargo. Piper Jaffray initiated the stock with “Overweight” rating in Monday, October 24 report. The stock of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) earned “Buy” rating by UBS on Monday, October 24.

Tabula Rasa HealthCare, Inc. , formerly CareKinesis, Inc., is a well-known provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The company has market cap of $268.60 million. The Firm delivers its solutions through a suite of technology-enabled services and products for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It currently has negative earnings. It also provides risk adjustment services, which help its clients to properly characterize a patient’s acuity, or severity of health condition, and optimize the associated payments for care.

Among 20 analysts covering Merck & Co. Inc. (NYSE:MRK), 15 have Buy rating, 1 Sell and 4 Hold. Therefore 75% are positive. Merck & Co. Inc. had 48 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Merck & Co., Inc. (NYSE:MRK) has “Overweight” rating given on Monday, September 21 by JP Morgan. The rating was maintained by BMO Capital Markets on Tuesday, June 6 with “Buy”. The rating was upgraded by Piper Jaffray on Thursday, January 12 to “Overweight”. Jefferies maintained Merck & Co., Inc. (NYSE:MRK) on Thursday, August 27 with “Hold” rating. BMO Capital Markets maintained the shares of MRK in report on Monday, June 12 with “Buy” rating. The rating was initiated by Societe Generale with “Buy” on Wednesday, April 6. The firm has “Buy” rating by Piper Jaffray given on Friday, July 28. As per Friday, April 15, the company rating was maintained by Jefferies. Argus Research maintained the shares of MRK in report on Tuesday, November 17 with “Buy” rating. Jefferies maintained the shares of MRK in report on Thursday, July 14 with “Hold” rating.